medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2009, Number 2

<< Back Next >>

Acta Med 2009; 7 (2)

Infection by HVP, vaccines and new trends

Rivera RP, Zúñiga LD

Language: Spanish
References: 28
Page: 89-95
PDF size: 73.60 Kb.


ABSTRACT

Cervical cancer (CC) is the second most common cancer in women, caused by oncogenic types of human papiloma virus. In 2002 was responsible for 274,000 deaths worldwide. Approximately 70% of the cases of CC are caused by the two most common oncogenic HPV types: 16 and 18. 10% are caused by the next most common types: 45 and 31. Although preventive strategies such as vaccination do not substitute screanning methods for CC, the development of these vaccines, designed to prevent infections caused by oncogenic types of HPV, have the potential to decrease morbidity and mortality associated with CC and precancerous lesions. Today are available in the market 2 types of vaccines: Gardasil® from Merck Pharmaceutical Laboratories and Cervarix® from Glaxo Smith Kline Laboratories. Recently, new tools have being developed to improve the safety and efficacy or the HPV vaccines. These advances include improving the antigenical selection, inclusion of coadjuvant agents to enhance the immunogenicity of the vaccine and investigation of new routes of administration. Clinical trials of the HPV vaccine, that have used these technology, reported excellent safety, immunogenicity and efficacy for prevention of HPV infections. Today, many research groups, have being investigating and developing therapeutic vaccines, than may change the course of this disease; nevertheless, we have a long road to walk in this area.


REFERENCES

  1. Einstein MH, Goldberg GL. Human papillomavirus and cervical neoplasia. Cancer Invest 2002; 20(7 8): 1080-1085.

  2. Franco EL, Franco ED, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001; 164(7).

  3. Koutsky LA. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102(5A): 3-8.

  4. Vizcaíno A, Moreno V, Bosch F, Muñoz N, Barros X, Parkin D. International trends in the incidence of cervical cancer. Int J Cancer 1998; 75: 536-545.

  5. Dirección General de Información y Evaluación del Desempeño. Secretaría de Salud. Salud: México 2001: Cáncer cervicouterino. SSA 2002.

  6. Muñoz N, Bosch F, Sanjosé S, Valadui P, Tormo J, Ascunce N y cols. El virus del papiloma humano en la etiología del cáncer cervicouterino. Bol of Sanit Panam 1993; 115(84): 301-308.

  7. Clifford GM, Smith JS, Plummer M et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88(1): 63-73.

  8. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening: a prospective study. Lancet 1999; 354: 20-25.

  9. Campio M et al. Clinical manifestations and natural history of genital human papillomavirus infection. Obstet Gynecol Clin North Am 1987; 14: 363-388.

  10. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-428.

  11. Sellors JW, Karwalajtys TL, Kaczorowski J et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003; 168(4): 421-425.

  12. Winer RL, Lee SK, Hughes JP et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157(3): 218-226.

  13. Schlect NF, Kulaga S, Robitaille J et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286: 3106-3114.

  14. Ley C, Bauer H, Reighold A. Determinants of HPV infections in young women. J Ntl Cancer Inst 1991; 3: 997-1000.

  15. Castellsague X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; (31): 20-28.

  16. Silins I, Ryd W, Strand A et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005; 116(1): 110-115.

  17. Syrjanen K. Human papillomavirus in genital carcinogenesis. Sex Trans Dis 1994; 21(2): 86-89.

  18. Muñoz N, Bosch FX, Castellsague X, Díaz M, de Sanjose S, Hammouda D et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285.

  19. Hines J, Schlegel R, Bennett A. Prospects for a vaccine against human papillomavirus. Obstet Gynecol 1995; 86: 860-866.

  20. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Álvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.

  21. Mao C, Koutsky L, Ault K, Wheeler C, Brown D et al. Efficacy of human papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia. A Randomized Controlled Trial. Obstet Gynecol 2006; 107: 18-27.

  22. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicenter phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.

  23. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004; 364: 1757-1765.

  24. Hampl M, Sarajuuri H, Wentzensen N, Bender H, Kueppers V. Effect of Human Papillomavirus Vaccines on Vulvar, Vaginal, and Anal Intraepithelial Lesions and Vulvar Cancer. Obstet Gynecol 2006; 108: 1361-1368.

  25. Noller KL. Cervical cytology screening and evaluation. Obstet Gynecol 2005; 106(2): 391-397.

  26. Brinkman JA, Hughes SH, Stone P, Caffrey AS, Muderspach LI, Roman LD, Weber JS, Kast WM. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 2007; 23: 337-352.

  27. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007; 7: 79-89.

  28. Kanodia S, Da Silva D et al. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008; 122: 247-259.




2020     |     www.medigraphic.com